New study aims to uncover hidden risks of kidney disease in american indians
NCT ID NCT04185844
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 500 American Indian adults with early kidney disease to learn how their condition progresses and what factors affect heart health. Researchers will measure kidney function and track heart events like heart attacks and strokes. The goal is to fill knowledge gaps about chronic kidney disease in this community.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal key risk factors for kidney and heart disease in American Indians, guiding future prevention and treatment strategies.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2020
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
American Indians at 3 sites.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Glomerular Filtration Rate (GFR): eGFR of =\>61\<80 and microalbuminuria \> 30 or eGRF of =\<60 (no microalbuminuria required). Exclusion Criteria: 1. Unable or unwilling to provide informed consent 2. life expectancy \<3 years; 3. institutionalized subjects; 4. End stage renal disease or renal transplant; 5. renal cancer; 6. myeloma; 7. immunosuppression; 8. Polycystic kidney disease; 9. participation in any clinical trial, 10. current pregnancy 11. current incarceration. 12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
First Nations Community Health Source
RECRUITINGAlbuquerque, New Mexico, 87108, United States
-
NIDDK-Phoenix Epidemiology and Clinical Research
NOT_YET_RECRUITINGPhoenix, Arizona, 85016, United States
-
Zuni Health Initiative Center
RECRUITINGBlack Rock, New Mexico, 87327, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sickle cell clues to diabetes risk hidden in DNA
- Could monthly texts and automatic risk scores stop heart attacks before they start?
- Can a food and friendship program slow kidney disease?
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Two eggs a day put to the test for heart health